ライフサイエンスコーパス: pantoprazole

1 tients to receive either daily IV placebo or pantoprazole.

2 er half-time for acid recovery observed with pantoprazole.

3 ucing agent was seen following inhibition by pantoprazole.

4 or omeprazole and approximately 46 hours for pantoprazole.

5 log-rank p = 0.33: adjusted hazard ratio for pantoprazole: 1.68 [95% CI, 0.97-2.90]; p = 0.06).

6 herapy group, 44 patients treated with 40 mg pantoprazole, 1000 mg amoxicillin and 500 mg clarithromy

7 Intravenous pantoprazole, 160-240 mg/day administered in divided dos

8 ted complication or pneumonia (placebo: 1 vs pantoprazole: 2), and one patient was diagnosed with Clo

9 vofloxacin (LVX) consumption were prescribed pantoprazole 40 mg 2x/day, amoxicillin 1000 mg 12/12 h a

10 ylori treatments (Group A, n = 103) received pantoprazole 40 mg 2x/day, amoxicillin 1000 mg 12/12 h a

11 ous patients were randomly allocated to PPI (pantoprazole 40 mg/day) or placebo for 12 months.

12 aily for the first 5 days, followed by 40 mg pantoprazole, 500 mg clarithromycin and 500 mg tinidazol

13 h at least one of the alternative PPIs (8/52 pantoprazole, 6/52 omeprazole, 5/52 esomeprazole, 3/52 r

14 inute infusions of the proton pump inhibitor pantoprazole (80-120 mg every 8-12 hours) in controlling

15 Pantoprazole, 80 mg every 12 hours, was effective in 17

16 valuates the evidence for the efficacy of IV pantoprazole, a PPI, in preventing ulcer rebleeding afte

17 of this study was to assess the efficacy of pantoprazole, a proton pump inhibitor, as an adjunct to

18 Whereas all PPIs bind to cysteine 813, pantoprazole additionally binds to cysteine 822, deeper

19 to evaluate benefit or harm associated with pantoprazole administration.

20 In conclusion, subjects receiving pantoprazole after elective EVL had significantly smalle

21 ded, randomized, placebo-controlled trial of pantoprazole after elective EVL.

22 erapy group, 126 patients treated with 40 mg pantoprazole and 1000 mg amoxicillin, twice daily for th

23 MAIN Ninety-one patients (49 pantoprazole and 42 placebo) from 10 centers in Canada,

24 Pantoprazole and omeprazole accounted for 62% and 9% of

25 -2-pyridyl)methylsulfinyl]-1H-benzimidazole (pantoprazole), and 2-[(4-(3-methoxypropoxy)-3-methyl)-2-

26 Subjects in the pantoprazole arm received 40 mg pantoprazole intravenous

27 Pantoprazole bound only to either cysteine 813 or 822 in

28 or equal to 48 hours to receive 40 mg of IV pantoprazole daily or placebo.

29 minutes) after an initial 80-mg intravenous pantoprazole dose.

30 red upward dose titration, 2 required 120 mg pantoprazole every 12 hours, and 2 required 80 mg every

31 travenously after EVL followed by 40 mg oral pantoprazole for 9 days.

32 cts who received high dose and non-high-dose pantoprazole for confirmed acute PU bleeding at a tertia

33 of new users of lansoprazole, omeprazole, or pantoprazole from the United Kingdom Clinical Practice R

34 umonia developed in 20.4% of patients in the pantoprazole group and 14.3% in the placebo group (p = 0

35 leeding developed in 6.1% of patients in the pantoprazole group and 4.8% in the placebo group (p = 1.

36 However, the ulcers in the pantoprazole group were on average half as large as in t

37 placebo has been inadequately evaluated, and pantoprazole has the potential to cause harm.

38 Omeprazole and pantoprazole have no activity.

39 ave demonstrated the efficacy of intravenous pantoprazole in maintaining adequate control of gastric

40 prazole initiators and 923,500 omeprazole or pantoprazole initiators.

41 jects in the pantoprazole arm received 40 mg pantoprazole intravenously after EVL followed by 40 mg o

42 Pantoprazole is effective in relieving upper and lower g

43 Intravenous non-high-dose pantoprazole is equally effective as high-dose pantopraz

44 Pantoprazole is frequently administered to critically il

45 The proton pump inhibitor, pantoprazole, is unique in that it binds cysteine 822, l

46 Prescription of omeprazole, pantoprazole, lansoprazole, esomeprazole, or rabeprazole

47 n contrast, recovery of acid secretion after pantoprazole may depend entirely on new protein synthesi

48 following inhibition by all PPIs, other than pantoprazole, may depend on both protein turnover and re

49 ansoprazole (n = 52), esomeprazole (n = 11), pantoprazole (n = 9), rabeprazole (n = 2), and omeprazol

50 C. difficile was identified in 4.1% pantoprazole patients and in 2.4% placebo patients (p =

51 and 12 GERD patients pre-treated with 40 mg pantoprazole (PPI) or placebo b.i.d. was performed.

52 The review concludes that IV pantoprazole provides an effective option in the treatme

53 t intermittent administration of intravenous pantoprazole, the first proton pump inhibitor available

54 harm with the prophylactic administration of pantoprazole to mechanically ventilated critically ill p

55 Patients were treated with pantoprazole until esophageal mucosal healing.

56 idence interval 8.1-12.4) than omeprazole or pantoprazole users (n = 193; 15.3 cases per 100,000 pers

57 r incidence of TB disease than omeprazole or pantoprazole users.

58 Administration of pantoprazole was not associated with any difference in r

59 ntoprazole is equally effective as high-dose pantoprazole when treating low risk patients with a Rock